# Michael J. Ginder

> Michael J. Ginder is a Series A investor at Sands Capital Ventures backing Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sands Capital Ventures](https://shizune.co/investors/profile/sands-capital-ventures)
- Location: Arlington, United States
- Total investments: 3
- Last investment: Oct 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michael-ginder-cfa-a7738b28

Michael J. Ginder is a Partner at Sands Capital Management.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 100% |
| Pharmaceutical | 3 | 100% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Life Science | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 33% |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Blue Earth Therapeutics | Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics. | $76.5M | Series A | Oct 30, 2024 |  |
| Inspirna | Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2) | $55.1M | Series D | Jul 11, 2022 |  |
| Prilenia | Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston. | $43M | Series B | Nov 03, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Bracco](https://shizune.co/investors/profile/bracco) — VC Fund, 2 deals together
- [ALS Investment Fund](https://shizune.co/investors/profile/als-investment-fund) — VC Fund, 1 deal together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together
- [Dreavent 6](https://shizune.co/investors/profile/dreavent-6) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together
- [Lepu Medical](https://shizune.co/investors/profile/lepu-medical) — VC Fund, 1 deal together

## About Sands Capital Ventures

VC Fund · Arlington, United States

Sands Capital is an active, long-term investor in innovative growth businesses. The approach combines rigorous fundamental analysis with inspired thinking to seek out businesses that are creating the future. They operate through two affiliates: Sands Capital Management, which focuses on investing in companies in the public market, and Sands CapitalVentures, which focuses on investing in companies in the private market. By enabling clients to participate in the growth of these businesses, its mission is to add value and enhance their wealth with prudence over time.

5 contacts available at Sands Capital Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Barron B. Martin, Jr. | Sr. Research Associate | https://shizune.co/investors/profile/barron-b-martin-jr |
| Christopher Eng | Principal | https://shizune.co/investors/profile/christopher-eng |
| Frank M. Sands, Jr. | Director | https://shizune.co/investors/profile/frank-sands |
| Mark McGovern | Venture Partner | https://shizune.co/investors/profile/mark-mcgovern |
| Michael J. Ginder | Partner | https://shizune.co/investors/profile/michael-j-ginder |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Michael J. Ginder invest in?

Michael J. Ginder invests primarily in Health Care, Pharmaceutical and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michael J. Ginder last invest?

The most recent investment recorded for Michael J. Ginder closed in Oct 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co